1. Home
  2. GAB vs TRVI Comparison

GAB vs TRVI Comparison

Compare GAB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Equity Trust Inc. (The)

GAB

Gabelli Equity Trust Inc. (The)

HOLD

Current Price

$5.54

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.29

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAB
TRVI
Founded
1986
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GAB
TRVI
Price
$5.54
$14.29
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$21.55
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
10.91%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.28
$5.38
52 Week High
$6.37
$16.12

Technical Indicators

Market Signals
Indicator
GAB
TRVI
Relative Strength Index (RSI) 43.01 51.15
Support Level $5.48 $10.07
Resistance Level $6.22 $16.12
Average True Range (ATR) 0.09 0.80
MACD -0.01 -0.05
Stochastic Oscillator 16.36 40.11

Price Performance

Historical Comparison
GAB
TRVI

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: